Literature DB >> 21490439

MYC and aggressive B-cell lymphomas.

Graham W Slack1, Randy D Gascoyne.   

Abstract

Rearrangement of the proto-oncogene MYC leads to MYC protein deregulation and is an important driver of oncogenic transformation. MYC rearrangement is a recurring genetic abnormality in several aggressive B-cell lymphomas including: Burkitt lymphoma, diffuse large B-cell lymphoma; B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma; rare de novo acute lymphoblastic lymphoma/leukemia, transformed follicular lymphoma, and plasmablastic lymphoma. Important distinctions in the role of MYC in these tumors likely reflect whether it is a primary or secondary genetic event. The presence of a MYC rearrangement in these diseases has diagnostic and prognostic implications and it is important for the practicing anatomic pathologist to be familiar with these issues when diagnosing aggressive B-cell lymphomas. This review provides a brief overview of MYC biology; shows the clinical and pathologic features of the aggressive B-cell lymphomas that harbor recurrent MYC rearrangements; explores the diagnostic and clinical implications of MYC rearrangements in these diseases; and outlines the techniques available to the anatomic pathologist to detect MYC deregulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490439     DOI: 10.1097/PAP.0b013e3182169948

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  45 in total

1.  Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.

Authors:  Song-Yi Choi; Seok Jin Kim; Won Seog Kim; Kihyun Kim; Young-Hyeh Ko
Journal:  Virchows Arch       Date:  2011-10-15       Impact factor: 4.064

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

3.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 4.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

5.  P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.

Authors:  Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

6.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

7.  Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Authors:  X Zhao; T Lwin; X Zhang; A Huang; J Wang; V E Marquez; S Chen-Kiang; W S Dalton; E Sotomayor; J Tao
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

8.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Adam M Petrich; Benjamin A Chu; Amir Behdad; Shaoying Li; L Jeffrey Medeiros; Ryan D Cassaday; Nishitha M Reddy; Martin A Bast; Julie M Vose; Kimberly R Kruczek; Scott E Smith; Priyank Patel; Francisco Hernandez-Ilizaliturri; Reem Karmali; Saurabh Rajguru; David T Yang; Joseph J Maly; Kristie A Blum; Weiqiang Zhao; Charles Vanslambrouck; Chadi Nabhan
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

9.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

Authors:  Xinwei Zhang; Xiaohong Zhao; Warren Fiskus; Jianhong Lin; Tint Lwin; Rekha Rao; Yizhuo Zhang; John C Chan; Kai Fu; Victor E Marquez; Selina Chen-Kiang; Lynn C Moscinski; Edward Seto; William S Dalton; Kenneth L Wright; Eduardo Sotomayor; Kapil Bhalla; Jianguo Tao
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.